Safety, tolerability, pharmacokinetics and pharmacodynamics of HSK31858, a novel oral dipeptidyl peptidase‐1 inhibitor, in healthy volunteers: An integrated phase 1, randomized, double‐blind, placebo‐controlled, single‐ and multiple‐ascending dose study

Ejemplares similares

• Randomised, phase 1 evaluation of the safety, tolerability, pharmacokinetics and pharmacodynamics of iptacopan in healthy volunteers
  por: Irina Baltcheva, et al.
  Publicado: (2026)
• Safety, tolerability and pharmacokinetics of DNDI‐6148, a novel agent for leishmaniasis: A randomized, controlled, single ascending dose study in healthy participants
  por: Jean‐Yves Gillon, et al.
  Publicado: (2025)
• Safety, tolerability, pharmacokinetics, pharmacodynamics and food effect of HRS‐1893, a cardiac myosin inhibitor, in healthy subjects
  por: Kexu Yang, et al.
  Publicado: (2026)
• Pharmacology and safety of TAS5315, a Bruton tyrosine kinase inhibitor, in healthy volunteers: First‐in‐human, randomized, ascending‐dose studies
  por: Yuji Kumagai, et al.
  Publicado: (2025)
• Development of a novel tyrosine kinase 2 inhibitor ARTS‐011 and its first‐in‐human single and multiple ascending dose Phase I study to evaluate the tolerability, safety, pharmacokinetic profile and food effects
  por: Zhili Jin, et al.
  Publicado: (2026)